Titan Pharmaceuticals, Inc. (TTNP) |
|
0.99 0.01 (1.02%)
|
02-03 15:11 |
|
Open: |
1.04 |
Pre. Close: |
0.98 |
|
High:
|
1.04 |
Low:
|
0.97 |
|
Volume:
|
56,689 |
Market Cap:
|
14(M) |
|
|
|
Technical analysis |
as of: 2023-02-03 2:50:56 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 1.27 One year: 1.48 |
| Support: |
Support1: 0.86  Support2: 0.73 |
| Resistance: |
Resistance1: 1.09 Resistance2: 1.27 |
| Pivot: |
0.96 |
| Moving Average: |
MA(5): 0.99  MA(20): 0.95
MA(100): 0.97 MA(250): 0.96 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 53.6 %D(3): 61.7 |
| RSI: |
RSI(14): 54.2 |
| 52-week: |
High: 1.59 Low: 0.34 |
| Average Vol(K): |
3-Month: 43 (K) 10-Days: 59 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ TTNP ] has closed below upper band by 45.7%. Bollinger Bands are 9.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.05 - 1.06 |
1.06 - 1.06 |
|
Low:
|
0.94 - 0.94 |
0.94 - 0.95 |
|
Close:
|
0.96 - 0.97 |
0.97 - 0.98 |
|
Company Description |
|
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California. |
Headline News |
Tue, 31 Jan 2023
Premarket Mover: Titan Pharmaceuticals, Inc. common stock (TTNP) Up 7.07% - InvestorsObserver
Fri, 27 Jan 2023
Theriva Biologics, Research Frontiers And 1 Other Penny Stock ... - Investing.com UK
Thu, 15 Dec 2022
Titan Pharmaceuticals Provides Shareholder Update - BioSpace
Mon, 12 Dec 2022
UPDATE -- Titan Pharmaceuticals Inc. Announces Licensing ... - GlobeNewswire
Thu, 28 Jul 2022
Titan Pharmaceuticals Inc (NASDAQ: TTNP) Receives FDA ... - BP Journal
Tue, 05 Jul 2022
Penny Stocks To Watch: Why KRKR, RMED, TYME, TTNP & ENDP Stock Are Moving - Penny Stocks
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
10 (M) |
|
% Held by Insiders
|
1.088e+007 (%) |
|
% Held by Institutions
|
25.6 (%) |
|
Shares Short
|
428 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-9.17e+006 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
267.2 |
|
Return on Equity (ttm)
|
-59.2 |
|
Qtrly Rev. Growth
|
740000 |
|
Gross Profit (p.s.)
|
-58.68 |
|
Sales Per Share
|
-116.13 |
|
EBITDA (p.s.)
|
-3.86726e+006 |
|
Qtrly Earnings Growth
|
-4.9 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-8 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.01 |
|
Price to Cash Flow
|
2.19 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
271610 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2020-11-30 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
